Compugen Ltd. (CGEN)
NASDAQ: CGEN · IEX Real-Time Price · USD
1.690
-0.060 (-3.43%)
At close: Jul 2, 2024, 4:00 PM
1.680
-0.010 (-0.59%)
After-hours: Jul 2, 2024, 4:47 PM EDT
Compugen Revenue
Revenue in the quarter ending March 31, 2024 was $2.56M, a -65.88% decrease year-over-year. In the year 2023, Compugen had annual revenue of $33.46M with 346.12% growth.
Revenue (ttm)
$33.46M
Revenue Growth
+346.12%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
151.31M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
Dec 31, 2020 | 2.00M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 17.80M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 712.00K | -8.57M | -92.33% |
Dec 31, 2015 | 9.28M | -3.09M | -24.99% |
Dec 31, 2014 | 12.37M | 8.82M | 248.46% |
Dec 31, 2013 | 3.55M | 3.31M | 1,366.53% |
Dec 31, 2012 | 242.00K | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 1.12M | 865.00K | 346.00% |
Dec 31, 2009 | 250.00K | -88.00K | -26.04% |
Dec 31, 2008 | 338.00K | 158.00K | 87.78% |
Dec 31, 2007 | 180.00K | -35.00K | -16.28% |
Dec 31, 2006 | 215.00K | -431.00K | -66.72% |
Dec 31, 2005 | 646.00K | -1.98M | -75.44% |
Dec 31, 2004 | 2.63M | -4.15M | -61.19% |
Dec 31, 2003 | 6.78M | -4.32M | -38.94% |
Dec 31, 2002 | 11.10M | -263.00K | -2.32% |
Dec 31, 2001 | 11.36M | 4.00M | 54.41% |
Dec 31, 2000 | 7.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
TruBridge | 336.45M |
OptiNose | 74.02M |
Metagenomi | 47.26M |
Stereotaxis | 27.10M |
Capricor Therapeutics | 27.10M |
TriSalus Life Sciences | 21.98M |
Vaxart | 8.89M |
CGEN News
- 15 days ago - Compugen to Present at Upcoming Antibody Industrial Symposium - PRNewsWire
- 4 weeks ago - Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig - PRNewsWire
- 6 weeks ago - Compugen Reports First Quarter 2024 Results - PRNewsWire
- 6 weeks ago - Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential - PRNewsWire
- 6 weeks ago - Compugen Appoints David Silberman as Chief Financial Officer - PRNewsWire
- 2 months ago - Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 - PRNewsWire
- 2 months ago - Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 - PRNewsWire
- 2 months ago - Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 - PRNewsWire